[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 1999

Regression of In-Transit Melanoma of the Scalp With Intralesional Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor

Author Affiliations

Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Dermatol. 1999;135(10):1276-1277. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-10-dlt1099

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine with multiple functions. It is produced by T cells, B cells, macrophages, mast cells, endothelial cells, and fibroblasts. Dranoff et al1 were the first to show the antitumor reactivity in B16 mice following active immunization with B16 melanoma cells transfected with the GM-CSF gene. Granulocyte-macrophage colony-stimulating factor has also been reported to accelerate pressure ulcer healing, and regression of metastatic carcinoma in skin appendages.2,3 Recently, Leong et al4 demonstrated that autologous tumor vaccine with local recombinant human GM-CSF (rhGM-CSF) injections resulted in tumor regression in patients with stage IV melanoma.